FOLR1 and neoplasm: (80) developed a fully human CAR composed of the human C4 FRα specific ScFv for treatment of mice with PC from OC, aiming to avoid transgene immunogenicity and “on-target, off-tumor” toxicity of CARs containing mouse-derived ScFvs and to facilitate the persistence and activity of αFR-targeted CAR T cells in humans.